Regulus Therapeutics reported a net loss of $9.6 million for Q1 2025, compared to $8.5 million in Q1 2024. The company announced its acquisition by Novartis for an initial payment of $7.00 per share in cash, with potential for an additional $7.00 per share through a CVR. Positive topline data from the Phase 1b MAD study of farabursen for ADPKD was also reported, showing a mechanistic dose response and halted kidney volume growth.

Regulus Therapeutics reported a net loss of $12.8 million for the fourth quarter of 2024, or $0.20 per share. The company ended the year with $75.8 million in cash, cash equivalents, and short-term investments, with a projected cash runway into early 2026. Key updates include positive interim data from the Phase 1b MAD trial of farabursen for ADPKD and agreement with the FDA on the design of a Phase 3 pivotal trial.

Regulus Therapeutics reported a net loss of $14.1 million for the third quarter ended September 30, 2024. The company's cash, cash equivalents, and investments totaled $87.3 million as of September 30, 2024, providing a cash runway into H1 2026. Enrollment was completed in the fourth cohort of the Phase 1b MAD clinical trial of RGLS8429 for ADPKD, with topline data expected in early 2025.

Regulus Therapeutics reported a net loss of $11.0 million for the second quarter of 2024 and ended the quarter with $95.9 million in cash, cash equivalents, and investments.

Regulus Therapeutics reported a net loss of $8.5 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $107.7 million as of March 31, 2024, providing a cash runway into H1 2026. The company is advancing its RGLS8429 program for ADPKD, with topline data from the third cohort of the Phase 1b MAD study expected in mid-2024.

Regulus Therapeutics reported positive topline data from their Phase 1b MAD study of RGLS8429, completed an oversubscribed $100 million private placement extending their cash runway into H1 2026, and completed enrollment of the third cohort of patients in the MAD study.

Regulus Therapeutics reported positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's cash, cash equivalents and short-term investments were $30.8 million as of September 30, 2023.

Regulus Therapeutics reported a net loss of $7.0 million for the second quarter of 2023, with research and development expenses at $5.0 million and general and administrative expenses at $2.3 million. The company's cash and cash equivalents totaled $37.3 million as of June 30, 2023, expected to fund operations into mid-2024. The company's RGLS8429 Phase 1b MAD study progresses with the first patient dosed in the second cohort.

Regulus Therapeutics reported a net loss of $7.1 million, or $0.42 per share, for the first quarter ended March 31, 2023. The company's cash and cash equivalents were $30.3 million as of March 31, 2023, which is expected to extend into mid-2024 with the $15.0 million private placement.

Regulus Therapeutics reported its Q4 and year-end 2022 financial results, highlighting the progress of its Phase 1b MAD study of RGLS8429 in ADPKD patients and key leadership appointments. The company ended the year with $39.2 million in cash, cash equivalents, and short-term investments.

Regulus Therapeutics reported a net loss of $7.6 million, or $0.50 per share, for the third quarter ended September 30, 2022. The company's cash, cash equivalents, and short-term investments totaled $45.3 million as of September 30, 2022, which is expected to fund planned activities through 2023. The company announced the dosing of the first patient in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

Regulus Therapeutics reported a net loss of $7.3 million, or $0.50 per share, and had $47.5 million in cash, cash equivalents and marketable securities as of June 30, 2022. The company also announced the dosing of the first subject in its Phase 1 SAD study of RGLS8429 for the treatment of ADPKD and the appointment of Amin Kamel, Ph.D., as Vice President, DMPK.

Regulus Therapeutics reported a net loss of $6.7 million, or $0.05 per share, for the first quarter ended March 31, 2022. The company's cash and cash equivalents totaled $53.9 million as of March 31, 2022. The FDA accepted the IND application for RGLS8429, and a research collaboration was entered with Brigham and Women’s Hospital.

Regulus Therapeutics reported a net loss of $7.1 million for Q4 2021. The company successfully completed a Pre-IND meeting with the FDA for its ADPKD program and closed a $34.6 million private placement of equity.

Regulus Therapeutics reported a net loss of $8.6 million, or $0.10 per share, for the third quarter ended September 30, 2021. The company had $35.8 million in cash and cash equivalents as of September 30, 2021. The company discontinued development of RGLS4326 to focus on RGLS8429.

Regulus Therapeutics reported a net loss of $6.0 million, or $0.08 per share, for the second quarter ended June 30, 2021. The company's cash and cash equivalents totaled $41.4 million as of June 30, 2021, and it expects its cash resources to fund planned activities into Q4 2022.

Regulus Therapeutics reported financial results for the first quarter ended March 31, 2021. Noteworthy is the data from the first cohort of the phase 1b clinical trial of RGLS4326 for ADPKD treatment, where mean increases in Polycystin 1 (PC1) and Polycystin 2 (PC2) were observed.

Regulus Therapeutics reported Q4 2020 revenue of $5.0 million, primarily from the achievement of an enrollment milestone and completion of material transfer to Sanofi. The company's cash and cash equivalents totaled $31.1 million as of December 31, 2020. Net loss for the quarter was $1.3 million, or $0.03 per share.

Regulus Therapeutics reported revenue of $5.0 million for the third quarter of 2020, primarily from the completion of material transfers to Sanofi. The company achieved milestones from its collaboration with Sanofi, reducing outstanding debt to $4.7 million and extending the interest-only period through the end of 2021. The first patient was dosed in the Phase 1b clinical trial of RGLS4326 for ADPKD.

Regulus Therapeutics reported their Q2 2020 financial results, highlighting the completion of dosing in the Phase 1 MAD clinical study for RGLS4326 and the FDA Orphan Drug Designation for RGLS4326 for ADPKD. They also appointed Dr. Denis Drygin as Chief Scientific Officer and are planning to initiate a Phase 1b study in patients with ADPKD.

Regulus Therapeutics reported its Q1 2020 financial results, with a net loss of $5.9 million, or $0.25 per share, and cash and cash equivalents of $28.1 million. The company initiated dosing of the third and final cohort in the Phase 1 multiple ascending dose clinical study for RGLS4326.

Regulus Therapeutics reported a net loss of $4.9 million for the fourth quarter of 2019. The company reinitiated its RGLS4326 Phase 1 study after the FDA lifted a partial clinical hold and closed a $26 million financing tranche.